ILMN Stock Analysis — Illumina
Sector: Healthcare
AI Verdict
You're paying a steep premium for Illumina at 36.4x forward earnings despite negative growth expectations—unless its sequencing ecosystem proves unshakeable, the numbers don't justify the price.
Competitive Moat
Illumina dominates the gene sequencing market with proprietary sequencing-by-synthesis technology and a locked-in ecosystem of consumables, making it the default platform for clinical and research genomics. Its installed base and recurring consumables revenue create high switching costs for labs and institutions.
Summary
RSI at 29.5 signals Illumina is deeply oversold despite an 85.32% rebound over the past year.
Where It Stands
Illumina trades at 36.4x next year's earnings—well above the healthcare sector median of 22x—while analysts expect -3.9% EPS growth and the RSI at 29.5 suggests the stock is oversold.
Key Metrics
- RSI: 29.5 — Oversold
- Trailing P/E: 35.0x
- Forward P/E: 36.4x
- Earnings Growth: -0.0%
- Revenue Growth: +0.0%
- Market Cap: $28.4B
- 1-Year Return: 85.32%
- 52-Week High: $207.00
- 52-Week Low: $88.00
Analyst Consensus
17 Buy · 8 Hold · 3 Sell (28 analysts)
Bull Case
The 85.32% one-year return shows buyers have stepped in hard, betting Illumina's moat can outlast near-term earnings declines.
Bear Case
With a forward P/E of 36.4x and negative -3.9% expected EPS growth, any further P/E compression to the sector median (22x) would imply a steep valuation reset.
Catalyst to Watch
Watch for regulatory or reimbursement decisions on clinical sequencing, as positive outcomes could stabilize earnings and justify the premium multiple.